15 July 2017
Salmeterol / Fluticasonee
Excellent based on 10 reviews
1 inh @ $84.46 per inh
Buy Advair Generic Tablets with our Product Satisfaction Guarantee. Advair Generic and Salmeterol / Fluticasonee drugs contain the same active substance
- Really Fast Delivery
- Discreet Packs
- Reliable Online Store
- Online Order Tracking
- Cheap Price Guarantee
- No Hidden Costs
General Info: Uses and Effects
Advair Generic contains two active substances: Salmeterol and Fluticasonee. Salmeterol is a drug that belongs to a group of long-acting bronchodilators and helps maintain the passage of airways in the lungs. In this way, the entry and exit of air into the lungs is facilitated. The effect of this substance lasts at least 12 hours. Fluticasonee is a substance belonging to the corticosteroid group and acts by reducing the inflammation of the lungs.
Advair is indicated for the prevention of respiratory problems in patients suffering from asthma or chronic obstructive pulmonary disease (COBP). The use of this medicament is indicated in symptomatic therapy in patients with COBP, who have FEV1 < 60% of the reference value (before bronchodilator use).
The drug is indicated for use in regular asthma therapy, when the use of combined drugs is justified (long-acting beta-2-agonist and inhalation corticosteroid) in following patients:
- In patients who did not achieve adequate control of the symptoms by using inhaled corticosteroids or short-acting inhaled beta-2-agonists "as needed".
- In patients in whom adequate symptoms control has already been achieved using inhaled corticosteroids and long-acting beta-2 agonists.
The use of Advair in the dose of 50mcg/100mcg is not intended for the treatment of adults and children with severe asthma.
Contraindications: Important to Know
The only known contraindication is positive allergy reaction to beta-2 agonists (such as Salmeterol) or corticosteroids (such as Fluticasonee).
The treatment with Advair should not be abruptly discontinued in patients with asthma due to the risk of exacerbation. The therapy should be gradually discontinued under the supervision of a physician. In patients with COBP, discontinuation of therapy may also be associated with symptomatic decompensation.
As with all corticosteroid inhalation medications, Advair should be used cautiously in patients with pulmonary tuberculosis. In rare cases, the drug may cause cardiac arrhythmias, e.g. supraventricular tachycardia and atrial fibrillation, as well as a mild transient decrease in serum potassium levels when used in high doses. Therefore, Advair should be used cautiously in patients with severe cardiovascular disorders, heart rhythm disorders, diabetes mellitus, thyrotoxicosis, and untreated hypokalaemia.
Instructions on Taking
Advair is intended only for inhalation use.
Patients must be aware that daily use of Advair is necessary in order to achieve the optimum benefit of therapy, even in the case of asymptomatic disease.
The patient's condition should be regularly controlled by the physician in order to determine the optimal dose of the drug and the dose should be changed exclusively in accordance with recommendations of your doctor. It is necessary to adjust the dosage of Advair to the lowest one that will maintain an effective control of the asthma symptoms. After establishing control of the symptoms using the lowest possible dose administered twice daily, the next therapeutic step should include testing the use of an inhaled corticosteroid alone. Alternatively, in patients requiring long-acting beta-2 agonists, Advair can be administered once a day, if that kind of a therapy is appropriate for the maintenance of asthma symptoms.
In the case of once daily administration, when the most of the asthma symptoms occur during the night, the dose of the drug should be administered in the evening, while in patients who experience most of the symptoms during the day, the dosage of Advair should be administered in the morning.
Patients should use Advair in a dose that contains the appropriate dosage of Fluticasonee propionate corresponding to the severity of the disease. Doctors prescribing medicine to patients suffering from asthma should take into account that the efficacy of Fluticasonee propionate corresponds to the efficacy of other inhaled corticosteroids when administering it at a dose of approximately half the daily dosage (expressed in micrograms) of other inhaled corticosteroids. For example, 100mcg of Fluticasonee propionate is approximately equivalent to 200mcg of Beclomethasone, Dipropionate or Budesonide.
The short-term use of Advair can be initiated in adults and adolescents with moderate persistent asthma (defined as everyday occurrence of symptoms in patients) that requires quick management of asthma symptoms. In these cases, the recommended initial dose is one inhalation of 50mcg of Salmeterol and 100mcg of Fluticasonee propionate administered twice daily. After establishing control of asthma symptoms, it is necessary to evaluate the benefits and consider the possibility of using inhaled corticosteroids alone as a monotherapy in these patients. It is important to regularly monitor the condition of patients after starting Advair.
In general, inhaled corticosteroids remain the first-line treatment of asthma in the majority of patients. Therefore, Advair is not intended for the initial treatment of a mild form of asthma. The use of Advair 50mcg/100mcg is not appropriate in adults and children with severe asthma; it is recommended to determine the appropriate dose of inhaled corticosteroids before applying any fixed therapeutic combination in patients with severe asthma.
Adults and adolescents aged 12 years and older:
- One inhalation of 50mcg of Salmeterol and 100mcg of Fluticasonee propionate administered twice daily.
- One inhalation of 50mcg of Salmeterol and 250mcg of Fluticasonee propionate administered twice daily.
- One inhalation of 50mcg of Salmeterol and 500mcg of Fluticasonee propionate administered twice daily.
The maximum recommended dose of Fluticasonee propionate in children older than 4 years is 100mcg administered twice daily. There are no data available on the use of Advair in children younger than 4 years.
The recommended dosage for the treatment of COBP in adults is one inhalation of 50mcg of Salmeterol and 500mcg of Fluticasonee propionate administered twice daily. There is no need to adjust the dose in elderly patients or in patients with renal impairment. There are no data available on the use of Advair in patients with hepatic impairment.
Advair (Salmeterol & Fluticasonee) can cause following side effects:
- Oral candidiasis;
- Rapid heart rate;
- Pharynx inflammation;
- Muscle cramps;
- Increased blood glucose levels;
- Decreased blood potassium levels.
1 July 2017
18 Jun 2017
4 Jun 2017
18 May 2017
4 May 2017
2 May 2017
14 Apr 2017
8 Apr 2017
25 Mar 2017